Clin2
NCT07283315Possibly a fitRecruiting

NK cell therapy for children with autoimmune diseases

Paediatric B Cell-related Autoimmune DiseasesAutoimmune DiseasesCAR

Part of Immune system & allergy clinical trials.

This trial tests a new treatment using special NK cells (a type of immune cell) designed to target and calm overactive B cells that cause autoimmune diseases like lupus and kidney inflammation. It may help children whose current treatments aren't working well enough.

Summary written for real people, not researchers, by Clin2.

Phase
Early Phase 1
Enrollment
12 people
Ages
3 years and older
Study type
Interventional

Who can take part

  • You must be at least 3 years old (or 5, depending on the specific disease).
  • Your heart, liver, kidneys, and lungs need to be working well enough.
  • If you are a girl who could become pregnant, you must use birth control or avoid pregnancy during the study and for 12 months after.
  • Your autoimmune disease must be moderate to severe and not well controlled with standard treatments.
  • You must not have serious infections, certain heart conditions, or active cancer.
  • You cannot have had an organ or stem cell transplant in the last 3 months.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06464679Recruiting· Phase 1
CD19 CAR NK cells for autoimmune diseases

This trial tests a new type of immune cell therapy (CD19 CAR NK cells) for people with certain autoimmune diseases that have not responded to standard treatments. The goal is to see if these cells can safely reduce disease activity.

Shanghai
NCT06792799Recruiting· Early Phase 1
CAR-NK cells for B-cell autoimmune diseases

This early phase trial tests a new treatment made from immune cells (CAR-NK cells) that target and destroy overactive B cells. It may help people with lupus, certain kidney diseases, or nephrotic syndrome that hasn't responded to standard therapies.

Hangzhou, Zhejiang
NCT07674147Not yet recruiting· Early Phase 1
CD19/BCMA CAR-T cell therapy for tough autoimmune diseases in kids

This trial tests a new type of cell therapy (CAR-T cells designed to target CD19 and BCMA) for children and teenagers with severe autoimmune diseases that have not gotten better with standard treatments. The goal is to see if this one-time infusion can help control the disease and reduce the need for long-term steroids and other drugs.

Nanjing, Jiangsu
NCT06318533Recruiting· Early Phase 1
Engineered immune cell therapy for autoimmune diseases

This early-stage study tests an experimental treatment that uses engineered immune cells (called CAR natural killer cells) to calm overactive immune responses in people with moderate to severe autoimmune diseases that have not fully responded to standard treatments. It aims to offer a new option for patients who have not gotten enough benefit from usual therapies.

Zhenjiang, Jiangsu
NCT07490041Recruiting· Early Phase 1
CAR-NK cell therapy for refractory childhood rheumatic diseases

This trial is testing a new type of cell therapy (CAR-NK cells) that targets two markers on immune cells (CD19 and BCMA) to treat severe forms of childhood rheumatic diseases. It aims to see if this treatment is safe and can help when other medicines have failed.

Hangzhou, Zhejiang
NCT06469190Recruiting· Early Phase 1
CAR NK cells for treatment-resistant kidney disease

This trial is testing a new therapy made from your own immune cells (called CAR NK cells) that are designed to fight a type of kidney disease that hasn't responded to standard treatments. It may be an option if you have membranous nephropathy, IgA nephropathy, or ANCA-associated vasculitis and previous treatments have failed.

Shanghai

Hear when a new Autoimmune Diseases trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.